key: cord-1051977-k7s48ukr authors: Savirón-Cornudella, Ricardo; Villalba, Ana; Zapardiel, Javier; Andeyro-Garcia, Mercedes; Esteban, Luis M.; Pérez-López, Faustino R. title: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during delivery date: 2020-12-01 journal: Eur J Obstet Gynecol Reprod Biol DOI: 10.1016/j.ejogrb.2020.11.069 sha: 2442d81aef25901d49746d6c16116a54ea2fa707 doc_id: 1051977 cord_uid: k7s48ukr OBJECTIVE: To screen pregnant women at risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during delivery using reverse-transcription polymerase chain reaction (RT-PCR) test and serum immunoglobulin (Ig) testing. METHOD: Between March 31 st and August 31 st of 2020, consecutive pregnant women admitted for labor and delivery in a single hospital were screened for SARS-CoV-2 with nasopharyngeal RT-PCR swab tests and detection of serum IgG and IgM. RESULTS: We studied 266 pregnant women admitted for labor and delivery. The prevalence of acute or past SARS-CoV-2 infection was 9.0 %, including (i) two cases with respiratory symptoms of SARS-Co-V-2 infection and positive RT-PCR; (ii) four asymptomatic women with positive RT-PCR without clinical symptoms and negative serological tests between two and 15 weeks later; and (iii) two women with false positive RT-PCR due to technical problems. All newborns of the 6 pregnant women with RT-PCR positive had negative RT-PCR and did not require Neonatal Intensive Care Unit admission. There were eighteen asymptomatic women with positive serological IgG tests and negative RT-PCR. CONCLUSION: In our cohort of gravids, we found 2.2% of women with positive RT-PRC tests and 6.7% with positive serological tests during the first wave of the SARS-CoV-2 pandemic. There are several strategies to diagnose the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection related to coronavirus disease and to identify the current or past infection and immune status. The preferred primary method for screening is the reverse-transcription polymerase chain reaction (RT-PCR) using upper respiratory samples via nasopharyngeal or oropharyngeal swabs [1, 2] . The procedure has been demonstrated to be highly specific (95%) [3, 4] and sensitive (70%) in samples from non-pregnant women [4] . The RT-PCR may detect the current or past presence of viral material whereas the serological tests assess the formation of antibodies to SARS-CoV-2 and may help to demonstrate a current infection [5] . The antibody tests for serum immunoglobulin (Ig) M (IgM), IgG, and IgA are based in the demonstration of those antibodies in human serum as a diagnostic tool of SARS-Co-V-2. These antibodies can be demonstrated in blood samples of patients RT-PCR positive 2-12 days after symptoms started and depending on sociodemographic factors [6] . In asymptomatic pregnant women admitted for delivery, the reported positive SARS-COV-2 screening with the RT-PCR tests is 86-88%, which is similar to those in the general population [7, 8] . However, the prevalence of those positive tests are variable depending on the study location and delivery facilities [8] [9] [10] [11] [12] . There are different techniques for antibody titration against SARS-CoV-2, including rapid IgM-IgG antibody tests, chemiluminescence immunoassay, and enzyme-linked immunosorbent assay (ELISA), and. The ELISA technique has a sensitivity of 89% and a specificity of 91% [13] , although it varies according on the day of analysis since symptoms onset [14] . The objective of the present study is to evaluate the clinical manifestations and the performance of two different tests, RT-PCR and serological testing, for screening of pregnant women admitted to the maternity ward for delivery. During the period of the study, 266 pregnant women admitted for labor and delivery were submitted to the SARS-Co-V-2 screening with RT-PCRs. The prevalence of acute or healed COVID-19 infection was 9.0 %, corresponding to 18 past SARS-CoV-2 exposures and six current infections (Figure 1 ). There were eight positive RT-PCR for SARS-CoV-2, although two of them were categorized as laboratory misinterpretation of results after women were discharged from the hospital. As expected, these two cases had no clinical symptoms and were negative for ELISA antibody tests. Therefore, we finally counted six positive RT-PCR women, of whom two had COVID-19 symptoms during labor or delivery (one patient was only IgM positive and the other had no serological test), and four were asymptomatic ( Table 1) . One of the two symptomatic cases with positive RT-PCR was diagnosed with intrauterine growth restriction. The four asymptomatic and positive RT-PCR pregnant women were negative in the ELISA study for both IgM and IgG during hospitalization. These four cases were submitted to second ELISA immune tests five to 15 weeks after delivery being negative once again. All six cases were vaginal deliveries without neonatal acidosis, no J o u r n a l P r e -p r o o f newborn required for admission to the Neonatal Intensive Care Unit, and also they all were RT-PCR negative. Symptomatic women were discharged on the third day and evolved favorably, as did their newborns. All negative RT-PCR cases (n = 260) were asymptomatic throughout the whole hospitalization and 18 of them were positive for IgG, being considered as past SARS-CoV-2 exposure. In a group of 266 pregnant women SARS-CoV-2 exposure was screened with RT-PCR tests during delivery. There were eight RT-PCR positive patients including two women with clinical evidence of SARS-CoV-2 infection, four past viral exposure and two false positive due to technical problems. All these 8 neonates were healthy without clinical signs of virus infection and negative RT-PCR tests. Serological IgG specific antibodies addressed against the SARS-CoV-2 were present in 18 women with negative RT-PCR tests. Therefore, the prevalence of acute or past SARS-CoV-2 infection was 9.0 % in our cohort, which is similar to the prevalence in non-pregnant subjects studied by seroprevalence in the Madrid area [15] . The maternal ELISA tests, in the four RT-PCR positive and asymptomatic, repeated 2-15 weeks after delivery were negative. Dust et al. [16] reported the performance of different commercial SARS-CoV-2 RT-PCR assays testing clinical samples and reference material, ranging the sensitivity from 24 copies/mL to 574/mL specimen. However, the RT-PCR sensitivity, specificity, and positive or negative predictive values are still very difficult to determine without clear gold standard tests for SARS-COV-2 [17] . Previous studies have described positive RT-PCR in asymptomatic pregnant women rates ranging between 50% and 89% [8, 9, 11, 12] , our 66.7 % in our small sample seems to fit well within reported ranges. still unknown for how long antibodies will be produced [20] . The serological test may reach a specificity of 98.7% depending on the timing of sampling [5] . during at least 14 days after clinical infection initiation [21] . In a meta-analysis, the pooled ELISA methods have a sensitivity of 84% for measuring IgG or IgM as compared to lateral flow immunoassays of 66.0% and chemiluminescent immunoassays of 97.8% in the general population [22] . Total antibody determination has low sensitivity during the first weeks with clinical symptoms (30.1%), increasing during the second week to reach the highest levels during the third week. There is limited information beyond 35 days postinitiation of clinical symptoms [5] . There is scarce information concerning the antibody formation dynamic in pregnant women with SARS-Co-V-2 infection around the period of delivery. In an unselected cohort of German pregnant women, Zollkau et al. [23] reported a total of 225 PCRs and 180 IgG tests, finding only one case with a positive IgG test. We detected positive IgG serological tests in 18 asymptomatic women. None of our asymptomatic patients with positive RT-PCR developed antibodies during the study period. Pregnant women are considered a relatively low-risk group for COVID-19 since they are generally young [24, 25] . However, there are also results suggesting that SARS-Co-V-2 is more likely associated with some adverse clinical conditions due to anatomic and physiological changes during pregnancy [26] . In addition, preeclampsia, excessive body weight and socioeconomic disparities may be potential cofactors to worsen the obstetric and perinatal results [27] . On the other hand, pregnant women during their third trimester of gestation and labor may display atypical features, including the absence of fever as well as leukocytosis. From our own experience, in asymptomatic patients with positive RT-PCR we have to review RT-PCR in search of false positives and take into account perform antibody tests. We had two false positive RT-PCR for misinterpreting the test during the period of maximum incidence of the pandemic and probably related to initial learning curve of the [28] or with lower viral load, which has been associated to lower rates of seropositivity [29] . New methods are currently under development to detect SARS-CoV-2 combining simplified extraction of RNA with reverse transcription followed by isothermal amplification and clustered regularly interspaced short palindromic repeats mediated detection. This new approach has a sensitivity of 93.1% and a specificity of 98.5% [30] . Our study point out the relevance in that RT-PCR and antibody serologies are techniques that can be complementary in some circumstances. In particular, antibodies would be indicated in symptomatic patients or with positive chest images with negative RT-PCR and in asymptomatic patients with positive RT-PCR to clarify false positives and negatives. The performance of antibodies has also allowed us to know which patients have overcome the disease. The pandemic nature of the COVID-19 has allowed designing different strategies to manage pregnant women according to available resources in different health care systems. We found that the systematic RT-PCR assessment and serological studies of SARS-CoV-2 seem appropriated to identify women at risk during labor and delivery. There were 2.2% of women with positive RT-PRC tests and 6.7% with positive serological tests during the first wave of the SARS-CoV-2 pandemic in Madrid. There is a need to contrast different J o u r n a l P r e -p r o o f international experiences to effectively define the better models of clinical assistance during pregnancy and delivery since the pandemic nature of the virus. RSC, JZ, MAG and FRPL contributed to the conception of the study. RSC, AV, LME and FRPL contributed to the design of the work. JZ and AV carried out data acquisition. All authors were involved in the interpretation of the study results, and the drafting and revision of the manuscript, and all approved the final version to be published. The authors report no conflicts of interest and are alone responsible for the content and the writing of the article. This research did not receive any specific grant or was funded by any commercial or non-profit organization or public agency. The study was approved by the Fundación Jiménez Díaz Clinical Research Ethics Committee, Madrid, Spain (protocol EO107-20). The present study was based on clinical results obtained during the COVID-19 pandemic. The authors report no conflicts of interest and are alone responsible for the content and the writing of the article. The coronavirus disease (COVID) 2019 and human pregnancy: A scoping review COVID-19 diagnosis and management: a comprehensive review Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases Detection of SARS-CoV-2 in different types of clinical specimens Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev SARS-CoV-2 seroprevalence among parturient women in Philadelphia. Sci Immunol Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Universal Screening for SARS-CoV-2 in Women Admitted for Delivery Screening for COVID-19 at childbirth: is it effective? Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization Universal screening for SARS-CoV-2 before labor admission during Covid-19 pandemic in Madrid Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in COVID-19 Antibody Testing in Pregnancy Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Comparison of Commercial Assays and Laboratory Developed Tests for Detection of SARS-CoV-2 Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review Falsenegative testing for severe acute respiratory syndrome coronavirus 2: consideration in obstetrical care False positives in reverse-transcription PCR testing for SARS-CoV-2. medRxiv Antibody responses to SARS-CoV-2 in patients with COVID-19 Clinical performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective analysis for the diagnosis of COVID-19 in a real-life routine care setting Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Periodenprävalenz von SARS-CoV-2 in einer unselektierten Stichprobe schwangerer Frauen in Jena, Thüringen [Period Prevalence of SARS-CoV-2 in an Unselected Sample of Pregnant Women in Jena Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis SARS-CoV-2 in pregnancy: characteristics and outcomes of hospitalized and non-hospitalized women due to COVID-19 Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons Detection of SARS-CoV-2 with SHERLOCK One-pot testing None J o u r n a l P r e -p r o o f